Workflow
维力医疗: 维力医疗关于对外投资设立境外孙公司暨关联交易的公告

Core Viewpoint - The company plans to establish a subsidiary in Indonesia through its wholly-owned subsidiary WELL LEAD GLOBAL LIMITED, with a total investment of 500 billion Indonesian Rupiah (approximately 20 million RMB) to build a production base [1][2][6]. Summary by Sections 1. Overview of Foreign Investment and Related Transactions - The investment aims to enhance the company's overseas production capabilities and service supply [2][6]. - The total investment is 500 billion Indonesian Rupiah, with WELL LEAD GLOBAL LIMITED contributing 475 billion Indonesian Rupiah (95% ownership) and Chairman Xiang Bin contributing 25 billion Indonesian Rupiah (5% ownership) [1][2]. 2. Approval Process - The investment was approved by the company's board of directors with 6 votes in favor and no opposition, and the related party Xiang Bin abstained from voting [3][8]. - The investment requires domestic and Indonesian regulatory approvals, including investment permits and company registration [3][6]. 3. Related Party Information - Xiang Bin is the chairman and actual controller of the company, holding 31.42% of the shares indirectly [4][6]. - The investment does not constitute a major asset restructuring as defined by regulations [4][6]. 4. Financial Data of the Investment Entity - WELL LEAD GLOBAL LIMITED has total assets of approximately 81.45 million RMB and net assets of about 40.10 million RMB as of December 31, 2024 [4]. - The company reported a net profit of 760,748.08 RMB for the first quarter of 2025 [4]. 5. Investment Agreement Details - The investment agreement stipulates that both parties will contribute funds based on the construction progress and operational needs of the Indonesian subsidiary [5][6]. - The agreement includes clauses for breach of contract and dispute resolution through negotiation or arbitration [6]. 6. Impact of the Investment - The establishment of the Indonesian subsidiary is a strategic move to expand international market reach and meet overseas customer demands [6][7]. - The investment will be funded entirely from the company's own resources, ensuring no adverse impact on daily cash flow or financial stability [7]. 7. Historical Related Transactions - There have been no significant related transactions with the same related party exceeding 30 million RMB in the past 12 months, aside from disclosed routine transactions [8][9].